レナサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/02/27 | 1,451 | 1,460 | 1,345 | 1,380 | -119 | -7.9% | 995,000 |
| 2025/02/26 | 1,456 | 1,519 | 1,420 | 1,499 | +56 | +3.9% | 1,088,500 |
| 2025/02/25 | 1,323 | 1,450 | 1,321 | 1,443 | +116 | +8.7% | 905,900 |
| 2025/02/21 | 1,322 | 1,390 | 1,286 | 1,327 | +4 | +0.3% | 628,500 |
| 2025/02/20 | 1,334 | 1,358 | 1,286 | 1,323 | -1 | -0.1% | 540,400 |
| 2025/02/19 | 1,407 | 1,473 | 1,297 | 1,324 | -83 | -5.9% | 1,210,100 |
| 2025/02/18 | 1,427 | 1,579 | 1,375 | 1,407 | -21 | -1.5% | 2,065,800 |
| 2025/02/17 | 1,565 | 1,758 | 1,372 | 1,428 | -97 | -6.4% | 3,996,000 |
| 2025/02/14 | 1,299 | 1,525 | 1,291 | 1,525 | +300 | +24.5% | 2,191,900 |
| 2025/02/13 | 1,316 | 1,316 | 1,170 | 1,225 | -72 | -5.6% | 730,200 |
| 2025/02/12 | 1,187 | 1,390 | 1,165 | 1,297 | +99 | +8.3% | 1,918,000 |
| 2025/02/10 | 1,155 | 1,247 | 1,144 | 1,198 | -15 | -1.2% | 944,200 |
| 2025/02/07 | 1,200 | 1,310 | 1,150 | 1,213 | -36 | -2.9% | 1,305,200 |
| 2025/02/06 | 1,199 | 1,399 | 1,173 | 1,249 | +49 | +4.1% | 2,204,800 |
| 2025/02/05 | 1,391 | 1,393 | 1,180 | 1,200 | -177 | -12.9% | 1,650,500 |
| 2025/02/04 | 1,585 | 1,667 | 1,206 | 1,377 | -48 | -3.4% | 4,732,100 |
| 2025/02/03 | 1,080 | 1,425 | 1,056 | 1,425 | +300 | +26.7% | 6,346,900 |
| 2025/01/31 | 1,185 | 1,500 | 1,125 | 1,125 | -400 | -26.2% | 5,619,200 |
| 2025/01/30 | 2,375 | 2,474 | 1,525 | 1,525 | -500 | -24.7% | 2,092,900 |
| 2025/01/29 | 1,705 | 2,025 | 1,650 | 2,025 | +400 | +24.6% | 5,385,900 |
| 2025/01/28 | 1,355 | 1,625 | 1,355 | 1,625 | +300 | +22.6% | 5,434,100 |
| 2025/01/27 | 1,160 | 1,340 | 1,142 | 1,325 | +285 | +27.4% | 7,793,200 |
| 2025/01/24 | 944 | 1,040 | 935 | 1,040 | +150 | +16.9% | 2,316,100 |
| 2025/01/23 | 944 | 1,004 | 865 | 890 | +36 | +4.2% | 7,138,600 |
| 2025/01/22 | 726 | 854 | 705 | 854 | +150 | +21.3% | 3,961,700 |
| 2025/01/21 | 586 | 704 | 571 | 704 | +100 | +16.6% | 2,340,300 |
| 2025/01/20 | 610 | 624 | 552 | 604 | -7 | -1.1% | 1,846,600 |
| 2025/01/17 | 641 | 709 | 570 | 611 | -40 | -6.1% | 9,004,900 |
| 2025/01/16 | 531 | 651 | 502 | 651 | +100 | +18.1% | 8,587,300 |
| 2025/01/15 | 642 | 642 | 508 | 551 | +9 | +1.7% | 7,294,800 |
| 2025/01/14 | 477 | 542 | 434 | 542 | +80 | +17.3% | 6,179,800 |
| 2025/01/10 | 446 | 462 | 430 | 462 | +80 | +20.9% | 1,746,600 |
| 2025/01/09 | 382 | 382 | 382 | 382 | +80 | +26.5% | 54,100 |
| 2025/01/08 | 311 | 312 | 302 | 302 | -9 | -2.9% | 77,300 |
| 2025/01/07 | 310 | 311 | 296 | 311 | +12 | +4% | 214,400 |
| 2025/01/06 | 302 | 304 | 297 | 299 | +2 | +0.7% | 39,200 |
| 2024/12/30 | 298 | 305 | 292 | 297 | +4 | +1.4% | 110,500 |
| 2024/12/27 | 292 | 293 | 277 | 293 | +25 | +9.3% | 241,100 |
| 2024/12/26 | 272 | 277 | 268 | 268 | -4 | -1.5% | 53,300 |
| 2024/12/25 | 270 | 275 | 269 | 272 | +3 | +1.1% | 109,800 |
| 2024/12/24 | 271 | 271 | 267 | 269 | -2 | -0.7% | 48,300 |
| 2024/12/23 | 276 | 280 | 270 | 271 | -5 | -1.8% | 43,500 |
| 2024/12/20 | 276 | 279 | 275 | 276 | -3 | -1.1% | 37,200 |
| 2024/12/19 | 274 | 279 | 263 | 279 | -1 | -0.4% | 61,200 |
| 2024/12/18 | 283 | 284 | 280 | 280 | -3 | -1.1% | 24,200 |
| 2024/12/17 | 284 | 286 | 281 | 283 | -1 | -0.4% | 34,100 |
| 2024/12/16 | 288 | 290 | 282 | 284 | -6 | -2.1% | 55,400 |
| 2024/12/13 | 299 | 299 | 290 | 290 | -6 | -2% | 32,600 |
| 2024/12/12 | 305 | 305 | 296 | 296 | -4 | -1.3% | 37,300 |
| 2024/12/11 | 298 | 300 | 295 | 300 | +2 | +0.7% | 25,300 |
151～
200
件表示中 / 989件
類似銘柄と比較する
現在ご覧いただいている「レナサイエンス」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| レナサイエンス | 203,400円 | -14.4% | - | 0.00% | - | 15.04倍 |
|
東北大発創薬ベンチャー。創業者の宮田同大教授が発見した低分子化合物を使い治療薬を開発 |
| アンジェス | 9,000円 | +110.0% | - | 0.00% | - | 10.46倍 |
|
大阪大医学部、森下竜一教授創業の創薬ベンチャー。遺伝子治療薬を核に核酸医薬など開発多彩 |
| ミズホメディ | 166,400円 | -20.7% | -41.2% | 5.71% | 14.18倍 | 1.84倍 |
|
体外検査薬専業、感染症抗体、遺伝子検査機器、試薬開発。新型コロナで急成長、妊娠検査薬も |
| ＣＡＮＢＡＳ | 106,100円 | - | - | 0.00% | - | 7.18倍 |
|
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索 |
| 扶桑薬 | 217,000円 | +1.6% | -12.7% | 4.15% | 8.06倍 | 0.56倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開 |
市場注目の銘柄
チャート関連のコラム
